Brokerages Set Geron Co. (GERN) Price Target at $3.75

Geron Co. (NASDAQ:GERN) has been assigned a consensus recommendation of “Hold” from the six ratings firms that are presently covering the stock, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $3.75.

A number of analysts have issued reports on the stock. Needham & Company LLC reiterated a “hold” rating on shares of Geron in a research note on Friday, November 3rd. Stifel Nicolaus reiterated a “hold” rating and set a $2.50 price target on shares of Geron in a research note on Friday, November 3rd. BidaskClub upgraded shares of Geron from a “sell” rating to a “hold” rating in a research note on Wednesday, January 24th. Finally, Zacks Investment Research lowered shares of Geron from a “buy” rating to a “hold” rating in a research note on Tuesday, January 2nd.

Several institutional investors have recently made changes to their positions in the company. Raymond James Financial Services Advisors Inc. grew its position in shares of Geron by 1.8% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 58,056 shares of the biopharmaceutical company’s stock worth $161,000 after buying an additional 1,000 shares in the last quarter. Voya Investment Management LLC grew its position in shares of Geron by 12.0% during the second quarter. Voya Investment Management LLC now owns 79,449 shares of the biopharmaceutical company’s stock worth $220,000 after buying an additional 8,534 shares in the last quarter. Alliancebernstein L.P. grew its position in shares of Geron by 6.9% during the second quarter. Alliancebernstein L.P. now owns 195,911 shares of the biopharmaceutical company’s stock worth $543,000 after buying an additional 12,600 shares in the last quarter. Wells Fargo & Company MN grew its position in shares of Geron by 13.7% during the second quarter. Wells Fargo & Company MN now owns 122,838 shares of the biopharmaceutical company’s stock worth $341,000 after buying an additional 14,800 shares in the last quarter. Finally, Northern Trust Corp grew its position in shares of Geron by 0.9% during the second quarter. Northern Trust Corp now owns 1,866,468 shares of the biopharmaceutical company’s stock worth $5,170,000 after buying an additional 16,561 shares in the last quarter. 39.08% of the stock is owned by institutional investors and hedge funds.

Shares of Geron (GERN) traded down $0.05 during trading hours on Friday, reaching $2.20. 1,977,100 shares of the company’s stock were exchanged, compared to its average volume of 2,831,151. The stock has a market capitalization of $350.31, a price-to-earnings ratio of -12.33 and a beta of 2.81. Geron has a one year low of $1.74 and a one year high of $3.15.

TRADEMARK VIOLATION NOTICE: “Brokerages Set Geron Co. (GERN) Price Target at $3.75” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of international trademark & copyright law. The correct version of this news story can be read at https://www.dispatchtribunal.com/2018/02/20/brokerages-set-geron-co-gern-price-target-at-3-75.html.

Geron Company Profile

Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc (Janssen). The Company is engaged in the development of therapeutic products for oncology. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that binds with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity.

Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply